Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MPL | P40238 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29893374 | 1.00 | ALDH1A1 (0.50) | ALDH1A1ADRA2BPTGS1TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL27585317 | 0.98 | ALDH1A1 (0.48) | ALDH1A1ADRA2BPTGS1TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL4379610 | 0.98 | ALDH1A1 (0.48) | ALDH1A1ADRA2BPTGS1TDP1KDM4E | |
| Aniline SCHEMBL22169117 | 0.92 | TSHR (0.44) | ALDH1A1ADRA2BPTGS1TDP1KDM4E | |
| SCHEMBL398120 | 0.83 | ALDH1A1 (0.52) | ALDH1A1ADRA2BPTGS1TDP1KDM4E | |
| SCHEMBL2848722 | 0.82 | MPL (0.41) | ALDH1A1ADRA2BPTGS1TDP1KDM4E | |
| SCHEMBL15391806 | 0.82 | ALDH1A1 (0.46) | ALDH1A1ADRA2BPTGS1TDP1KDM4E | |
| SCHEMBL2091208 | 0.82 | ALDH1A1 (0.46) | ALDH1A1ADRA2BPTGS1TDP1KDM4E | |
| SCHEMBL29201487 | 0.82 | ALDH1A1 (0.46) | ALDH1A1ADRA2BPTGS1TDP1KDM4E | |
| SCHEMBL4654446 | 0.82 | RXRA (0.47) | ALDH1A1KDM4EMAPTMPLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 982 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528777-B2 | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2026-01-20 | — | — | US | claimed |
| CN-120064487-A | Detection method of 4-trifluoromethoxy aniline related substances | 石家庄四药有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-118772041-A | Bisphenol compound with halogen-containing side groups, and preparation method and application thereof | 中国科学院大连化学物理研究所 | 2024-10-15 | — | — | CN | claimed |
| CN-114324620-B | Method for detecting p-trifluoromethoxy aniline and related impurities | 鲁南制药集团股份有限公司 | 2024-10-11 | — | — | CN | claimed |
| CN-116162203-B | High Tg cycloolefin copolymer and preparation method thereof | 宁夏清研高分子新材料有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-117185967-A | Preparation method of 2-trifluoromethoxybenzene sulfonamide | 大连奇凯医药科技有限公司 | 2023-12-08 | — | — | CN | claimed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | claimed |
| EP-3612180-B1 | SUBSTITUTED 2-ACYLAMINO-CYCLOALKYLTHIOPHENE-3-CARBOXYLIC ACID ARYLAMIDES AS INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNEL TMEM16A | UNIV CALIFORNIA (US) | 2023-10-11 | — | — | EP | claimed |
| CN-116162203-A | High Tg cycloolefin copolymer and preparation method thereof | 宁夏清研高分子新材料有限公司 | 2023-05-26 | — | — | CN | claimed |
| EP-4171569-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | Council of Scientific & Industrial Research (IN) | 2023-05-03 | — | — | EP | claimed |
| WO-2002042303-A2 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-05-30 | — | — | WO | claimed |
| US-6365780-B1 | DIAZOTIZATION OF AN ANILINE DIREVITIVE USING AN ALKYL NITRITE AND HYDROGEN CHLORIDE AND DECOMPOSITION OF THE DIAZONIUM SALT IN PRESENCE OF SULPHUR DIOXIDE, A SOLVENT AND COPPER CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | claimed |
| EP-0820981-B1 | Process for the preparation of 2-trifluoromethoxy-aniline | BAYER AG (DE) | 2000-10-18 | — | — | EP | claimed |
| US-6121492-A | Method for preparing 2-trifluoro-methoxy-aniline | RHODIA CHIMIE (FR) | 2000-09-19 | — | — | US | claimed |
| EP-0984920-A1 | NOVEL METHOD FOR PREPARING 2-TRIFLUORO-METHOXY-ANILINE | RHODIA CHIMIE (FR) | 2000-03-15 | — | — | EP | claimed |
| EP-0983982-A1 | Process for the preparation of aromatic or heteroaromatic sulfonyl chlorides | Bayer Aktiengesellschaft (DE) | 2000-03-08 | — | — | EP | claimed |
| WO-1998054121-A1 | NOVEL METHOD FOR PREPARING 2-TRIFLUORO-METHOXY-ANILINE | RHODIA-CHIMIE (FR) | 1998-12-03 | — | — | WO | claimed |
| US-5840983-A | Process for preparing 2-trifluoromethoxy-aniline | BAYER AKTIENGESELLSCHAFT (DE) | 1998-11-24 | — | — | US | claimed |
| EP-0820981-A1 | Process for the preparation of 2-trifluoromethoxy-aniline | BAYER AG (DE) | 1998-01-28 | — | — | EP | claimed |
| EP-0546391-A2 | Process for the preparation of fluorine containing anilines. | BAYER AG (DE) | 1993-06-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | ALDH1A1 295/4885ADRA2B 2560/4885PTGS1 2008/4885 |
| US-12528777-B2 | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof | ATG7, GOT1, ULK1 | ALDH1A1 601/4885ADRA2B 2755/4885PTGS1 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.